JP6118327B2 - 自動放射性医薬品合成装置を操作する方法 - Google Patents
自動放射性医薬品合成装置を操作する方法 Download PDFInfo
- Publication number
- JP6118327B2 JP6118327B2 JP2014533627A JP2014533627A JP6118327B2 JP 6118327 B2 JP6118327 B2 JP 6118327B2 JP 2014533627 A JP2014533627 A JP 2014533627A JP 2014533627 A JP2014533627 A JP 2014533627A JP 6118327 B2 JP6118327 B2 JP 6118327B2
- Authority
- JP
- Japan
- Prior art keywords
- data
- radiopharmaceutical
- synthesizer
- synthesis
- data collection
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Active
Links
- 238000000034 method Methods 0.000 title claims description 97
- 239000012217 radiopharmaceutical Substances 0.000 title claims description 79
- 229940121896 radiopharmaceutical Drugs 0.000 title claims description 78
- 230000002799 radiopharmaceutical effect Effects 0.000 title claims description 78
- 238000013480 data collection Methods 0.000 claims description 76
- 230000008569 process Effects 0.000 claims description 70
- 238000003786 synthesis reaction Methods 0.000 claims description 65
- 230000015572 biosynthetic process Effects 0.000 claims description 64
- 238000003908 quality control method Methods 0.000 claims description 29
- 238000002603 single-photon emission computed tomography Methods 0.000 claims description 15
- 238000004458 analytical method Methods 0.000 claims description 12
- 238000012937 correction Methods 0.000 claims description 8
- 230000002285 radioactive effect Effects 0.000 claims description 7
- 238000012544 monitoring process Methods 0.000 claims description 4
- 239000003814 drug Substances 0.000 claims 1
- 230000000694 effects Effects 0.000 description 65
- 238000004519 manufacturing process Methods 0.000 description 19
- 238000002414 normal-phase solid-phase extraction Methods 0.000 description 19
- 238000005259 measurement Methods 0.000 description 14
- 238000000746 purification Methods 0.000 description 14
- 238000002600 positron emission tomography Methods 0.000 description 13
- 238000006243 chemical reaction Methods 0.000 description 10
- 238000012360 testing method Methods 0.000 description 10
- 239000000523 sample Substances 0.000 description 9
- 230000000875 corresponding effect Effects 0.000 description 8
- 239000012535 impurity Substances 0.000 description 8
- 238000012986 modification Methods 0.000 description 7
- 230000004048 modification Effects 0.000 description 7
- 230000009471 action Effects 0.000 description 5
- 239000002131 composite material Substances 0.000 description 5
- 238000007405 data analysis Methods 0.000 description 5
- HUMNYLRZRPPJDN-UHFFFAOYSA-N benzaldehyde Chemical compound O=CC1=CC=CC=C1 HUMNYLRZRPPJDN-UHFFFAOYSA-N 0.000 description 4
- 201000010099 disease Diseases 0.000 description 4
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 4
- 238000002372 labelling Methods 0.000 description 4
- 238000010606 normalization Methods 0.000 description 4
- 238000011084 recovery Methods 0.000 description 4
- 238000003860 storage Methods 0.000 description 4
- 238000013024 troubleshooting Methods 0.000 description 4
- -1 2- [ 18 F] fluoroethyl Chemical group 0.000 description 3
- 230000008859 change Effects 0.000 description 3
- 230000007547 defect Effects 0.000 description 3
- 239000002243 precursor Substances 0.000 description 3
- 239000000700 radioactive tracer Substances 0.000 description 3
- IJGRMHOSHXDMSA-UHFFFAOYSA-N Atomic nitrogen Chemical compound N#N IJGRMHOSHXDMSA-UHFFFAOYSA-N 0.000 description 2
- KRHYYFGTRYWZRS-UHFFFAOYSA-M Fluoride anion Chemical compound [F-] KRHYYFGTRYWZRS-UHFFFAOYSA-M 0.000 description 2
- 230000004075 alteration Effects 0.000 description 2
- 239000002872 contrast media Substances 0.000 description 2
- 238000001514 detection method Methods 0.000 description 2
- 238000010828 elution Methods 0.000 description 2
- NTEDWGYJNHZKQW-DGMDOPGDSA-N fluciclovine ((18)F) Chemical compound OC(=O)[C@]1(N)C[C@H]([18F])C1 NTEDWGYJNHZKQW-DGMDOPGDSA-N 0.000 description 2
- 229940027541 fluciclovine f-18 Drugs 0.000 description 2
- 230000006870 function Effects 0.000 description 2
- 238000003384 imaging method Methods 0.000 description 2
- QNGNSVIICDLXHT-UHFFFAOYSA-N para-ethylbenzaldehyde Natural products CCC1=CC=C(C=O)C=C1 QNGNSVIICDLXHT-UHFFFAOYSA-N 0.000 description 2
- 239000000376 reactant Substances 0.000 description 2
- 239000000126 substance Substances 0.000 description 2
- 238000012546 transfer Methods 0.000 description 2
- UXCAQJAQSWSNPQ-KXMUYVCJSA-N 1-[4-fluoranyl-5-(hydroxymethyl)oxolan-2-yl]-5-methylpyrimidine-2,4-dione Chemical compound O=C1NC(=O)C(C)=CN1C1OC(CO)C([18F])C1 UXCAQJAQSWSNPQ-KXMUYVCJSA-N 0.000 description 1
- NTEDWGYJNHZKQW-KWCOIAHCSA-N 1-amino-3-fluoranylcyclobutane-1-carboxylic acid Chemical compound OC(=O)C1(N)CC([18F])C1 NTEDWGYJNHZKQW-KWCOIAHCSA-N 0.000 description 1
- CEIVUGLBKBWVAE-KXMUYVCJSA-N 2-amino-9-[3-(fluoranylmethyl)-4-hydroxybutyl]-3h-purin-6-one Chemical compound N1C(N)=NC(=O)C2=C1N(CCC(CO)C[18F])C=N2 CEIVUGLBKBWVAE-KXMUYVCJSA-N 0.000 description 1
- JXPDNDHCMMOJPC-UHFFFAOYSA-N 2-hydroxybutanedinitrile Chemical compound N#CC(O)CC#N JXPDNDHCMMOJPC-UHFFFAOYSA-N 0.000 description 1
- 125000001622 2-naphthyl group Chemical group [H]C1=C([H])C([H])=C2C([H])=C(*)C([H])=C([H])C2=C1[H] 0.000 description 1
- YJZYDPRMWYWYCG-KPVNRNJOSA-N 4-fluoranyl-n-[2-[4-(2-methoxyphenyl)piperazin-1-yl]ethyl]-n-pyridin-2-ylbenzamide Chemical compound COC1=CC=CC=C1N1CCN(CCN(C(=O)C=2C=CC([18F])=CC=2)C=2N=CC=CC=2)CC1 YJZYDPRMWYWYCG-KPVNRNJOSA-N 0.000 description 1
- 208000024827 Alzheimer disease Diseases 0.000 description 1
- 235000006506 Brasenia schreberi Nutrition 0.000 description 1
- 206010028980 Neoplasm Diseases 0.000 description 1
- QJGQUHMNIGDVPM-BJUDXGSMSA-N Nitrogen-13 Chemical compound [13N] QJGQUHMNIGDVPM-BJUDXGSMSA-N 0.000 description 1
- GKLVYJBZJHMRIY-OUBTZVSYSA-N Technetium-99 Chemical compound [99Tc] GKLVYJBZJHMRIY-OUBTZVSYSA-N 0.000 description 1
- 230000002159 abnormal effect Effects 0.000 description 1
- KRHYYFGTRYWZRS-BJUDXGSMSA-N ac1l2y5h Chemical compound [18FH] KRHYYFGTRYWZRS-BJUDXGSMSA-N 0.000 description 1
- 238000013459 approach Methods 0.000 description 1
- 238000004364 calculation method Methods 0.000 description 1
- 201000011510 cancer Diseases 0.000 description 1
- OKTJSMMVPCPJKN-BJUDXGSMSA-N carbon-11 Chemical compound [11C] OKTJSMMVPCPJKN-BJUDXGSMSA-N 0.000 description 1
- 239000003153 chemical reaction reagent Substances 0.000 description 1
- 150000001875 compounds Chemical class 0.000 description 1
- 230000001143 conditioned effect Effects 0.000 description 1
- 230000002596 correlated effect Effects 0.000 description 1
- 230000007423 decrease Effects 0.000 description 1
- 238000003745 diagnosis Methods 0.000 description 1
- 238000010586 diagram Methods 0.000 description 1
- 238000009826 distribution Methods 0.000 description 1
- 238000001035 drying Methods 0.000 description 1
- 238000013399 early diagnosis Methods 0.000 description 1
- 238000000605 extraction Methods 0.000 description 1
- 238000003682 fluorination reaction Methods 0.000 description 1
- 238000009472 formulation Methods 0.000 description 1
- 230000005251 gamma ray Effects 0.000 description 1
- 239000007789 gas Substances 0.000 description 1
- 238000002347 injection Methods 0.000 description 1
- 239000007924 injection Substances 0.000 description 1
- 150000002500 ions Chemical class 0.000 description 1
- 230000001678 irradiating effect Effects 0.000 description 1
- 230000009191 jumping Effects 0.000 description 1
- 239000000203 mixture Substances 0.000 description 1
- 229910052757 nitrogen Inorganic materials 0.000 description 1
- QVGXLLKOCUKJST-BJUDXGSMSA-N oxygen-15 atom Chemical compound [15O] QVGXLLKOCUKJST-BJUDXGSMSA-N 0.000 description 1
- 238000011165 process development Methods 0.000 description 1
- 230000002250 progressing effect Effects 0.000 description 1
- 238000000275 quality assurance Methods 0.000 description 1
- 230000005258 radioactive decay Effects 0.000 description 1
- 238000000163 radioactive labelling Methods 0.000 description 1
- 239000002287 radioligand Substances 0.000 description 1
- 230000001105 regulatory effect Effects 0.000 description 1
- 239000013557 residual solvent Substances 0.000 description 1
- 238000012776 robust process Methods 0.000 description 1
- 230000035945 sensitivity Effects 0.000 description 1
- 239000007790 solid phase Substances 0.000 description 1
- 239000000243 solution Substances 0.000 description 1
- 239000002904 solvent Substances 0.000 description 1
- 229950001675 spiperone Drugs 0.000 description 1
- 230000002194 synthesizing effect Effects 0.000 description 1
- 230000009897 systematic effect Effects 0.000 description 1
- 229940056501 technetium 99m Drugs 0.000 description 1
- 238000003325 tomography Methods 0.000 description 1
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 1
Classifications
-
- B—PERFORMING OPERATIONS; TRANSPORTING
- B01—PHYSICAL OR CHEMICAL PROCESSES OR APPARATUS IN GENERAL
- B01J—CHEMICAL OR PHYSICAL PROCESSES, e.g. CATALYSIS OR COLLOID CHEMISTRY; THEIR RELEVANT APPARATUS
- B01J19/00—Chemical, physical or physico-chemical processes in general; Their relevant apparatus
- B01J19/0046—Sequential or parallel reactions, e.g. for the synthesis of polypeptides or polynucleotides; Apparatus and devices for combinatorial chemistry or for making molecular arrays
-
- G—PHYSICS
- G16—INFORMATION AND COMMUNICATION TECHNOLOGY [ICT] SPECIALLY ADAPTED FOR SPECIFIC APPLICATION FIELDS
- G16H—HEALTHCARE INFORMATICS, i.e. INFORMATION AND COMMUNICATION TECHNOLOGY [ICT] SPECIALLY ADAPTED FOR THE HANDLING OR PROCESSING OF MEDICAL OR HEALTHCARE DATA
- G16H40/00—ICT specially adapted for the management or administration of healthcare resources or facilities; ICT specially adapted for the management or operation of medical equipment or devices
- G16H40/40—ICT specially adapted for the management or administration of healthcare resources or facilities; ICT specially adapted for the management or operation of medical equipment or devices for the management of medical equipment or devices, e.g. scheduling maintenance or upgrades
-
- G—PHYSICS
- G21—NUCLEAR PHYSICS; NUCLEAR ENGINEERING
- G21G—CONVERSION OF CHEMICAL ELEMENTS; RADIOACTIVE SOURCES
- G21G1/00—Arrangements for converting chemical elements by electromagnetic radiation, corpuscular radiation or particle bombardment, e.g. producing radioactive isotopes
- G21G1/0005—Isotope delivery systems
Landscapes
- Chemical & Material Sciences (AREA)
- Health & Medical Sciences (AREA)
- Engineering & Computer Science (AREA)
- Organic Chemistry (AREA)
- Biomedical Technology (AREA)
- General Business, Economics & Management (AREA)
- Business, Economics & Management (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Primary Health Care (AREA)
- Medical Informatics (AREA)
- Epidemiology (AREA)
- Nuclear Medicine (AREA)
- Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
Description
合成装置におけるSPEプロセス等の精製プロセスの調節等のプロセス開発、
ロバスト性試験:放射活性検出器のそれぞれについてのデータのグラフ表示はプロセスの「指紋」のようなものであるから、ロバスト性のあるプロセスは運転間で殆ど偏りを示さない、
トラブル解決:確立されたデータに基づく成功した製造からの放射活性検出器のばらつきの傾向から、放射性合成における問題が発見され、突き止められる、
PETセンターのセットアップのサポート、
製造量の保証は患者のニーズに合致する(例えば適切な数の患者用量が製造されることの保証)、
異なる合成装置の成績を決定するための、種々の場所における放射活性検出器の傾向の同定、
合成装置のハードウェアの問題の同定、
合成装置のシーケンスファイルプログラミング課題の同定、
合成後の品質管理の単純化、
遠隔地における顧客サポートの提供、
データ収集ファイル、例えばログファイルの正規化。
活性検出器No.1に対する相関係数:100/80=1.25
活性検出器No.2に対する相関係数:100/110=0.91
活性検出器No.5に対する相関係数:100/90=1.11。
Claims (10)
- 放射性医薬品合成プロセスを監視する方法であって、
1つ以上のコンピュータプロセッサによって放射性医薬品合成装置から放射性医薬品合成プロセスに関するデータを受け取るステップと、
データを解析するステップと、
データの1つ以上の特徴であって、放射性医薬品合成プロセスに関連する品質管理因子と関連する1つ以上の特徴を同定するステップと、
データの1つ以上の特徴を抽出するステップと、
抽出されたデータを解析するステップと、
抽出されたデータの解析に基づいて補正因子を決定するステップと、
放射性医薬品合成において補正因子を実行するステップと
を含んでおり、抽出されたデータを解析するステップが、異なる位置における異なる合成装置間の比較ができるように相関係数又は正規化係数を計算することを含む、方法。 - 放射性医薬品合成装置からデータを電子的に受け取るステップであって、データが放射性医薬品システムから電子的に送信されるステップを含む、請求項1記載の方法。
- データが、放射性医薬品合成装置に設置された複数の放射性検出器を用いて放射性医薬品プロセスの間に測定される、請求項1又は請求項2記載の方法。
- 抽出されたデータが、放射性医薬品合成プロセスの収率に関連する、請求項1乃至請求項3のいずれか1項記載の方法。
- 抽出されたデータが、放射性医薬品合成プロセスからの放射性医薬品生成物の純度に関連する、請求項1乃至請求項4のいずれか1項記載の方法。
- データがデータ収集ファイルを構成する、請求項1乃至請求項5のいずれか1項記載の方法。
- データが、放射性医薬品合成の間に1秒間隔で測定され記録されたデータ点を含む、請求項1乃至請求項6のいずれか1項記載の方法。
- 補正が、放射性医薬品合成装置によって自動的に実行される、請求項1乃至請求項7のいずれか1項記載の方法。
- 放射性医薬品合成装置が、SPECT又はPETスキャンの実施に関して用いられる特定の放射性医薬品を製造するために構成されている、請求項1乃至請求項8のいずれか1項記載の方法。
- 放射性医薬品がSPECT又はPET放射性医薬品である、請求項1乃至請求項9のいずれか1項記載の方法。
Applications Claiming Priority (3)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US201161541296P | 2011-09-30 | 2011-09-30 | |
US61/541,296 | 2011-09-30 | ||
PCT/US2012/056868 WO2013048954A1 (en) | 2011-09-30 | 2012-09-24 | Method of operating an automated radiopharmaceutical synthesizer |
Publications (2)
Publication Number | Publication Date |
---|---|
JP2015501462A JP2015501462A (ja) | 2015-01-15 |
JP6118327B2 true JP6118327B2 (ja) | 2017-04-19 |
Family
ID=47144077
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
JP2014533627A Active JP6118327B2 (ja) | 2011-09-30 | 2012-09-24 | 自動放射性医薬品合成装置を操作する方法 |
Country Status (5)
Country | Link |
---|---|
US (2) | US10029228B2 (ja) |
EP (1) | EP2761514B1 (ja) |
JP (1) | JP6118327B2 (ja) |
CN (1) | CN103946851B (ja) |
WO (1) | WO2013048954A1 (ja) |
Families Citing this family (5)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
EP2761514B1 (en) | 2011-09-30 | 2020-11-11 | GE Healthcare Limited | Method of operating an automated radiopharmaceutical synthesizer |
EP3532803B9 (en) * | 2016-09-19 | 2023-02-22 | Siemens Medical Solutions USA, Inc. | Flexible application of cross-calibration for quantitative functional imaging |
US10245002B2 (en) * | 2017-08-01 | 2019-04-02 | Siemens Medical Solutions Usa, Inc. | Isotope specific calibration of a dose calibrator for quantitative functional imaging |
GB201805283D0 (en) * | 2018-03-29 | 2018-05-16 | Ge Healthcare Ltd | Method of synthesizing a radiopharmaceutical |
US11615882B2 (en) | 2018-11-07 | 2023-03-28 | Ge Healthcare Limited | Apparatus, non-transitory computer-readable storage medium, and computer-implemented method for distributed ledger management of nuclear medicine products |
Family Cites Families (12)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US5440478A (en) * | 1994-02-22 | 1995-08-08 | Mercer Forge Company | Process control method for improving manufacturing operations |
US5532941A (en) | 1994-07-08 | 1996-07-02 | Lin; Lawrence I. | Inter-laboratory performance monitoring system |
JP2003022115A (ja) * | 2001-07-05 | 2003-01-24 | Natl Inst Of Radiological Sciences | 短寿命放射性薬剤製造のための全体制御システム及び短寿命放射性薬剤製造のための時間短縮方法 |
WO2005082253A1 (en) * | 2004-02-20 | 2005-09-09 | Philips Intellectual Property & Standards Gmbh | Drug application during a ct scan |
US9627097B2 (en) * | 2004-03-02 | 2017-04-18 | General Electric Company | Systems, methods and apparatus for infusion of radiopharmaceuticals |
US20050232387A1 (en) * | 2004-04-20 | 2005-10-20 | Padgett Henry C | Microfluidic apparatus and method for synthesis of molecular imaging probes |
JP4524389B2 (ja) * | 2004-08-18 | 2010-08-18 | 独立行政法人放射線医学総合研究所 | 放射性標識薬自動合成装置 |
US7741121B2 (en) * | 2006-08-24 | 2010-06-22 | Siemens Medical Solutions Usa, Inc. | System for purification and analysis of radiochemical products yielded by microfluidic synthesis devices |
US7519492B2 (en) * | 2007-05-02 | 2009-04-14 | General Electric Company | Apparatus and method for fully automated closed system quality control of a substance |
WO2010021719A1 (en) * | 2008-08-19 | 2010-02-25 | The Regents Of The University Of California | Modular radiochemistry synthesis system |
US8214159B2 (en) * | 2008-12-04 | 2012-07-03 | Siemens Medical Solutions Usa, Inc. | Apparatus and method for automated quality control |
EP2761514B1 (en) | 2011-09-30 | 2020-11-11 | GE Healthcare Limited | Method of operating an automated radiopharmaceutical synthesizer |
-
2012
- 2012-09-24 EP EP12783401.8A patent/EP2761514B1/en active Active
- 2012-09-24 WO PCT/US2012/056868 patent/WO2013048954A1/en active Application Filing
- 2012-09-24 US US14/348,690 patent/US10029228B2/en active Active
- 2012-09-24 JP JP2014533627A patent/JP6118327B2/ja active Active
- 2012-09-24 CN CN201280058713.2A patent/CN103946851B/zh active Active
-
2018
- 2018-07-23 US US16/042,626 patent/US10758887B2/en active Active
Also Published As
Publication number | Publication date |
---|---|
EP2761514B1 (en) | 2020-11-11 |
US10758887B2 (en) | 2020-09-01 |
US20190001296A1 (en) | 2019-01-03 |
US10029228B2 (en) | 2018-07-24 |
EP2761514A1 (en) | 2014-08-06 |
WO2013048954A1 (en) | 2013-04-04 |
US20140257566A1 (en) | 2014-09-11 |
CN103946851B (zh) | 2018-03-13 |
JP2015501462A (ja) | 2015-01-15 |
CN103946851A (zh) | 2014-07-23 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
JP6018637B2 (ja) | 放射性医薬品合成装置のための較正及び正規化システム及び方法 | |
US10758887B2 (en) | Method of operating an automated radiopharmaceutical synthesizer | |
US11170884B2 (en) | Control system for radiopharmaceuticals | |
Franc et al. | Small-animal SPECT and SPECT/CT: important tools for preclinical investigation | |
US20130053994A1 (en) | Method and apparatus for monitoring radiopharmaceutical processing | |
KR20170093777A (ko) | 핵의학 화상 데이터의 정량화 | |
Chakravarty et al. | Clinical 68Ga-PET: is radiosynthesis module an absolute necessity? | |
Jackson et al. | In Silico approaches for addressing challenges in cns radiopharmaceutical design | |
US20210020271A1 (en) | Method of synthesizing a radiopharmaceutical | |
Thompson et al. | Equipment and instrumentation for radiopharmaceutical chemistry | |
Kovac et al. | A simple and efficient automated cGMP‐compliant radiosynthesis of [11C] metomidate using solid phase extraction cartridge purification | |
Zagni et al. | The concept of minimum detectable activity of radionuclide activity meters and their suitability for routine quality control of radiopharmaceuticals. An experimental study | |
JP6751758B2 (ja) | 塩素同位体36を含有する放射性廃棄物をインサイチュー分析する装置および方法 | |
Shetty et al. | Tandem Mass Spectrometry as an Independent Method for Corroborating Fluorine-18 Radioactivity Measurements in Positron Emission Tomography | |
Roig et al. | Measurement of 173Lu (n, γ) Cross Sections at DANCE |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
A621 | Written request for application examination |
Free format text: JAPANESE INTERMEDIATE CODE: A621 Effective date: 20150916 |
|
A977 | Report on retrieval |
Free format text: JAPANESE INTERMEDIATE CODE: A971007 Effective date: 20160817 |
|
A131 | Notification of reasons for refusal |
Free format text: JAPANESE INTERMEDIATE CODE: A131 Effective date: 20160920 |
|
A601 | Written request for extension of time |
Free format text: JAPANESE INTERMEDIATE CODE: A601 Effective date: 20161219 |
|
A521 | Request for written amendment filed |
Free format text: JAPANESE INTERMEDIATE CODE: A523 Effective date: 20170217 |
|
TRDD | Decision of grant or rejection written | ||
A01 | Written decision to grant a patent or to grant a registration (utility model) |
Free format text: JAPANESE INTERMEDIATE CODE: A01 Effective date: 20170307 |
|
A61 | First payment of annual fees (during grant procedure) |
Free format text: JAPANESE INTERMEDIATE CODE: A61 Effective date: 20170324 |
|
R150 | Certificate of patent or registration of utility model |
Ref document number: 6118327 Country of ref document: JP Free format text: JAPANESE INTERMEDIATE CODE: R150 |
|
R250 | Receipt of annual fees |
Free format text: JAPANESE INTERMEDIATE CODE: R250 |
|
R250 | Receipt of annual fees |
Free format text: JAPANESE INTERMEDIATE CODE: R250 |
|
R250 | Receipt of annual fees |
Free format text: JAPANESE INTERMEDIATE CODE: R250 |
|
R250 | Receipt of annual fees |
Free format text: JAPANESE INTERMEDIATE CODE: R250 |
|
R250 | Receipt of annual fees |
Free format text: JAPANESE INTERMEDIATE CODE: R250 |